Iterum receives Nasdaq delisting notice, hearing set for Nov 21 on equity compliance

Iterum Therapeutics plc

Nasdaq notified Iterum on Oct 1 of delisting for failing to meet $2.5M stockholders' equity requirement after Sep 30 extension deadline.
Company requested hearing; Nasdaq Hearings Panel will consider appeal on November 21, 2024.
Trading of ITRM ordinary shares continues on Nasdaq Capital Market pending hearing outcome.
Panel may grant compliance extension up to March 31, 2025, but no assurance of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.